Most guidelines suggest avoiding GLP-1 drugs in chronic pancreatitis, though exceptions may exist for carefully selected patients with minimal remaining pancreatic function loss
BPC-157's documented effects on tendon, ligament, and muscle healing in preclinical models make it a compound of interest for patients who are placing new demands on connective tissues as their body composition changes
Our team is here to support you.
Molecules 25:2540
However, human clinical trials remain limited and results are inconsistent
This slowing contributes to the appetite suppression that drives weight loss and the postprandial glucose-lowering effect, and it also drives most of the gastrointestinal side effect profile.[1],[2] A 2025 review in the Journal of Clinical Endocrinology & Metabolism summarizes the published evidence: GLP-1 receptor agonists impact gastric, intestinal, and gallbladder motility simultaneously, with effects on gastric fundus relaxation, antral contractility inhibition, increased pyloric tone, and reduced small intestinal motility.[3] The path from this mechanism to constipation is straightforward